- Home
- GABC vs IMTX Comparison
GABC vs IMTX Comparison
Compare GABC & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GABC | IMTX |
|---|---|---|
| Founded | 1910 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | GABC | IMTX |
|---|---|---|
| Price | $43.77 | $11.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.67 | $19.00 |
| AVG Volume (30 Days) | 78.6K | ★ 489.7K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 8.13 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $487,401,000.00 | N/A |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $3.98 | $25.91 |
| P/E Ratio | $49.28 | ★ N/A |
| Revenue Growth | ★ 37.80 | N/A |
| 52 Week Low | $36.65 | $5.05 |
| 52 Week High | $45.00 | $12.41 |
Technical Indicators
Market Signals| Indicator | GABC | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 53.17 |
| Support Level | $42.06 | $9.05 |
| Resistance Level | $44.68 | $11.54 |
| Average True Range (ATR) | 0.85 | 0.57 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 89.66 | 63.98 |
Price Performance
Historical ComparisonAbout GABC German American Bancorp Inc.
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.